Ascendis Pharma A/S ASND
Ascendis Pharma A/S (Nasdaq: ASND) is a rare genetic drug developer. Its lead program, TransCon CNP (navepegritide), is in Phase 3 for achondroplasia in children. Its next catalyst on record is TransCon CNP (navepegritide): Final European Commission decision on TransCon CNP MAA expected during Q4 2026. (Q4 2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: TransCon CNP (navepegritide) — Final European Commission decision on TransCon CNP MAA expected during Q4 2026. (Q4 2026). 3 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| TransCon CNP (navepegritide) | achondroplasia | unclear | Phase 3 |
Recent results and decisions
- Nov 6, 2026positive EMA COMP adopts positive opinion recommending maintenance of orphan designation for TransCon CNP for achondroplasia, with final EC decision expected in Q4 2026.
The Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending maintenance of orphan medicinal product designation for once-weekly TransCon CNP (navepegritide) as a treatment for achondroplasia in children.
Filing - Oct 26, 2026positive TransCon PTH demonstrated early, sustained, and clinically meaningful improvements in kidney function in adults with hypoparathyroidism treated for up to 5 years in pooled Phase 2 PaTH Forward and Phase 3 PaTHway trials.
Mean improvement in eGFR for all patients from baseline to Week 26 was 7.2 mL/min/1.73 m2 and to Week 52 was 9.6 mL/min/1.73 m2.
Filing - Oct 16, 2026positive CHMP adopts positive opinion recommending EU marketing authorization for once-weekly TransCon CNP for achondroplasia in children aged two years and older with open epiphyses, with EC decision expected in Q4 2026.
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending marketing authorization for once-weekly TransCon CNP (navepegritide) in the European Union for the treatment of achondroplasia in children two years of age and
Filing
9 more on record.
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 3 rare genetic companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.